Table S1 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases

Table S1 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases

<p>Supplementary Table S1</p>

Shranjeno v:

Bibliografske podrobnosti
Glavni avtor:	Noor Jailkhani (16015810) (author)
Drugi avtorji:	Karl R. Clauser (16015813) (author), Howard H. Mak (14958336) (author), Steffen Rickelt (14942629) (author), Chenxi Tian (16015816) (author), Charles A. Whittaker (15038249) (author), Kenneth K. Tanabe (16015819) (author), Stephen R. Purdy (16015822) (author), Steven A. Carr (14942649) (author), Richard O. Hynes (14942641) (author)
Izdano:	2025
Teme:	Cancer Tumor Biology Molecular and Cellular Biology Immuno-oncology Methods and Technology Breast Cancer Imaging Positron emission tomography (PET) Small animal imaging Immunology Antibodies/immunoconjugates Proteomics Tumor Microenvironment
Oznake:	Označite Brez oznak, prvi označite!

Podobne knjige/članki

Table S2 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
od: Noor Jailkhani (16015810)
Izdano: (2025)

Table S3 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
od: Noor Jailkhani (16015810)
Izdano: (2025)

Supplementary Video S1 from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
od: Xiaojiang Duan (15439264)
Izdano: (2025)

Supplementary Video S2A from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
od: Xiaojiang Duan (15439264)
Izdano: (2025)

Supplementary Video S2B from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
od: Xiaojiang Duan (15439264)
Izdano: (2025)

Supplementary Video S2C from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
od: Xiaojiang Duan (15439264)
Izdano: (2025)

FigureS1 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
od: Jonathan Chou (14957015)
Izdano: (2025)

FigureS10 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
od: Jonathan Chou (14957015)
Izdano: (2025)

FigureS2 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
od: Jonathan Chou (14957015)
Izdano: (2025)

FigureS3 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
od: Jonathan Chou (14957015)
Izdano: (2025)

FigureS4 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
od: Jonathan Chou (14957015)
Izdano: (2025)

FigureS5 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
od: Jonathan Chou (14957015)
Izdano: (2025)

FigureS6 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
od: Jonathan Chou (14957015)
Izdano: (2025)

FigureS7 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
od: Jonathan Chou (14957015)
Izdano: (2025)

FigureS8 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
od: Jonathan Chou (14957015)
Izdano: (2025)

FigureS9 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
od: Jonathan Chou (14957015)
Izdano: (2025)

Supplementary MovieS 1a from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
od: Jonathan Chou (14957015)
Izdano: (2025)

Supplementary MovieS1b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
od: Jonathan Chou (14957015)
Izdano: (2025)

Supplementary MovieS1c from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
od: Jonathan Chou (14957015)
Izdano: (2025)

Supplementary MovieS1d from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
od: Jonathan Chou (14957015)
Izdano: (2025)

Supplementary MovieS2a from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
od: Jonathan Chou (14957015)
Izdano: (2025)

Supplementary MovieS2b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
od: Jonathan Chou (14957015)
Izdano: (2025)

Supplementary MovieS2c from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
od: Jonathan Chou (14957015)
Izdano: (2025)

Supplementary Data S1 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
od: Steven B. Maron (15044607)
Izdano: (2025)

Alternative Ion-Pairing Modifiers Should Be Investigated in Low-Input and Single-Cell Proteomics
od: Colten D. Eberhard (17729446)
Izdano: (2025)

Quantitative Proteomics Links Mitochondrial Dysfunction to Metabolic Changes and Epithelial Differentiation Defects in Hyperoxia-Exposed Neonatal Airway Cells
od: Abhrajit Ganguly (21540245)
Izdano: (2025)

Table 1_Cerebrospinal fluid proteomic profiling reveals potential biomarkers and altered pathways in myotonic dystrophy type 1.docx
od: Marwa Zafarullah (12527002)
Izdano: (2025)

Figure 1 from Imaging Glioblastoma Response to Radiotherapy Using <sup>2</sup>H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
od: Friederike Hesse (14958870)
Izdano: (2025)

Figure 2 from Imaging Glioblastoma Response to Radiotherapy Using <sup>2</sup>H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
od: Friederike Hesse (14958870)
Izdano: (2025)

Figure 3 from Imaging Glioblastoma Response to Radiotherapy Using <sup>2</sup>H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
od: Friederike Hesse (14958870)
Izdano: (2025)

Figure 4 from Imaging Glioblastoma Response to Radiotherapy Using <sup>2</sup>H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
od: Friederike Hesse (14958870)
Izdano: (2025)

Figure 5 from Imaging Glioblastoma Response to Radiotherapy Using <sup>2</sup>H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
od: Friederike Hesse (14958870)
Izdano: (2025)

Figure 6 from Imaging Glioblastoma Response to Radiotherapy Using <sup>2</sup>H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
od: Friederike Hesse (14958870)
Izdano: (2025)

Figure 7 from Imaging Glioblastoma Response to Radiotherapy Using <sup>2</sup>H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
od: Friederike Hesse (14958870)
Izdano: (2025)

Table 1 from Imaging Glioblastoma Response to Radiotherapy Using <sup>2</sup>H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
od: Friederike Hesse (14958870)
Izdano: (2025)

Figure 1 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
od: Vinton W.T. Cheng (15020397)
Izdano: (2025)

Figure 2 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
od: Vinton W.T. Cheng (15020397)
Izdano: (2025)

Figure 3 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
od: Vinton W.T. Cheng (15020397)
Izdano: (2025)

Figure 4 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
od: Vinton W.T. Cheng (15020397)
Izdano: (2025)

Figure 5 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
od: Vinton W.T. Cheng (15020397)
Izdano: (2025)

Cannot write session to /tmp/vufind_sessions/sess_nd876t7c0b20is3ik5qm3lio66